Arterius

What Arterius does

Arterius is a privately held medical device company headquartered in Leeds, United Kingdom, developing two proprietary polymer technology platforms for vascular intervention: an advanced polymer coating technology applied to Drug Coated Balloons (DCBs) for efficient single- or dual-drug delivery to the vessel wall, and ArterioSorb™, a bioresorbable scaffold (stent) manufactured from PLLA polymer using a patented 'solid phase orientation' production process that achieves 95-micron strut thickness while delivering radial force comparable to metal stents for a 3–6 month remodeling window before full resorption. Both platforms target peripheral arterial disease and are designed to leave no permanent implant, addressing long-term complications of metallic stents such as side-branch occlusion and the inefficiency of existing drug-coated balloons that deliver only a small fraction of drug to tissue. The company has obtained EN ISO 13485:2016 certification (November 2023) for the design, development, and pre-clinical/clinical evaluation of these products and is currently funded through grant and equity capital.

Arterius operates a pre-commercial, R&D-stage business model with no disclosed revenue, pricing, or distribution channels; products are not yet approved and the December 2025 Innovate UK grant covers the GLP preclinical study described as the final stage before first-in-human trials. Future end-customers are expected to be hospitals, interventional cardiology and vascular surgery departments treating peripheral arterial disease, accessed via partnership with established medical device distributors once regulatory clearances are obtained. The company has raised over £10 million cumulatively from Innovate UK grants, Deepbridge Capital LLP (an EIS/SEIS investment manager), and Novoline d.o.o, and collaborates with five UK universities (Southampton, Bradford, Nottingham, Bristol, Imperial College London) on core polymer R&D. Leadership is anchored by founder and CTO Dr. Kadem Al-Lamee (40+ years in biomaterials), with Chair Barry Clare (ex-Boots Healthcare International), CFO Gerard Harper, Operations Director Nial Bullett, and senior independent NED Peter Mason (Barclays Investment Banking).

Name

Arterius

Legal name

Arterius Limited

Website

https://arterius.co.uk

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

1–10 employees

Short description

Arterius is a Leeds, UK-based medical device company developing proprietary polymer platforms—a Drug Coated Balloon with efficient drug-transfer coating and the ArterioSorb™ bioresorbable PLLA scaffold—for treating peripheral arterial disease without permanent implants.

Ownership category

akta.pro rank

Product category

Vascular Intervention Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Coronary Stents & Drug-Eluting Technologies (HLAHAFAA)

akta.pro secondary industry

Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy) (HLAHAFAE)

Keywords

• Bioresorbable scaffolds
• Drug-coated balloons
• Vascular intervention devices
• Polymer medical devices
• Peripheral arterial stents

Headquarters

HQ city

Leeds

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others, Marketing or Sales, Infrastructure

Marketing channels3 records

Core offering

Arterius develops next-generation polymer-based medical devices for vascular intervention, focused on the treatment of peripheral arterial disease. Its two core technology platforms are ArterioSorb™, a bioresorbable scaffold (stent) made from PLLA polymer that provides temporary vessel support for 3-6 months before being fully resorbed, and a Drug Coated Balloon (DCB) catheter using proprietary polymer coating technology that enables efficient single- and dual-drug delivery to vessel walls.

Product overview

Arterius offers two advanced polymer technology platforms for medical devices: ArterioSorb™ (a bioresorbable scaffold made with PLLA that holds vessels open for 3–6 months before full resorption) and a Drug Coated Balloon system featuring proprietary polymer coating technology for efficient multi-drug delivery to vessel walls. Both products target peripheral arterial disease treatment and are designed to leave no long-term implants in the body.

Differentiator

Problem solved

Functional benefit

Brands

• ArterioSorb™: Bioresorbable scaffold (stent) that holds the vessel open for 3-6 months before being fully resorbed by the body, made with PLLA biocompatible polymer.

Products and services

• ArterioSorb™ Bioresorbable Scaffold (BRS) A bioresorbable scaffold (stent) made with PLLA polymer that holds the vessel open for 3-6 months while it remodels, before being fully resorbed by the body, intended for the treatment of peripheral arterial disease. Manufactured using a patented 'solid phase orientation' production process that enables a 95-micron strut thickness (reducing thrombosis risk) and a wide diameter range (2-8mm) with variable cell design for flexibility and structural support.
• Drug Coated Balloon (DCB) catheter A special angioplasty balloon catheter coated with Arterius' proprietary polymer coating technology that enables efficient transfer of one or more drugs into the vessel wall, intended for the treatment of peripheral arterial disease. Compatible with existing regulator-approved PTA or PTCA balloon platforms and with both nylon and Pebax™ balloon substrates; supports dual-drug therapy for long-term inhibition of restenosis and reduced risk of local thrombus formation.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered major.

• University of SouthamptonmajorStrategic or Co-development PartnerAcademic partner in development of core polymer technologies. Collaboration during development of polymer coating technology and bioresorbable scaffold.
• University of BradfordmajorStrategic or Co-development PartnerAcademic partner collaborating on development of core polymer technologies for medical devices.
• University of NottinghammajorStrategic or Co-development PartnerAcademic partner in polymer technology development collaboration for medical device applications.
• University of BristolmajorStrategic or Co-development PartnerAcademic partner collaborating on development of core technologies for medical devices.
• Imperial College LondonmajorStrategic or Co-development PartnerAcademic partner in technology development collaboration.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat4 records

Key risks3 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/arterius-ltd

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arterius